SLU-PP-332 Overview
Category:
Experimental small-molecule / research peptide analogue — ERR agonist
How It Works:
Potent pan-agonist of estrogen-related receptors (ERRα, β, γ) that activates transcriptional programs for energy metabolism, mitochondrial biogenesis, and oxidative pathways.
Alternative Names:
ERR pan-Agonist 332, SR9861, (E)-4-Hydroxy-N′(naphthalen-2-ylmethylene)benzohydrazide
Primary Research Focus:
- Metabolic signaling
- Exercise mimetics
- Mitochondrial biogenesis
- Fat oxidation
- Metabolic syndrome models
Potential Risks:
No approved human trials; safety, tolerability, and dosing unestablished; human data lacking. Available data are from preclinical models or research settings only.
What It Is
SLU-PP-332 is an experimental compound used in laboratory and preclinical research to probe estrogen-related receptor signaling and metabolism. It most strongly activates ERRα — nuclear receptors that regulate genes involved in mitochondrial energy production, oxidative metabolism, and aerobic capacity.
Although often discussed with “peptide” communities, SLU-PP-332 is a small synthetic molecule with peptide-like research uses rather than a traditional polypeptide chain. Its core appeal in research is how it mimics molecular signals usually triggered by aerobic exercise, promoting enhanced cellular energy use and metabolic adaptations.
How It Works in the Body
SLU-PP-332 binds to estrogen-related receptors ERRα, ERRβ, and ERRγ, which are regulators of genes linked to mitochondrial biogenesis (creation of new mitochondria), fatty acid oxidation, and glucose metabolism. Activation of these pathways leads to increased transcription of PGC-1α and TFAM, crucial drivers of mitochondrial replication and oxidative respiration.
Through this mechanism, SLU-PP-332 shifts energy use toward oxidation of fats, enhances resting energy expenditure, and induces adaptations similar to endurance exercise — without physical training. In preclinical models, this results in higher oxidative capacity and improved metabolic flexibility.
SLU-PP-332 Benefits
Below are key effects observed in research contexts, mainly in animal or cell-based models:
Enhanced Mitochondrial Function
SLU-PP-332 upregulates pathways that increase mitochondrial number, improve oxidative phosphorylation, and boost ATP production — essential for energy-intensive tissues like muscle and heart.
Fatty Acid Oxidation & Energy Expenditure
Studies show significant increases in lipid oxidation rates and resting energy use, lowering the respiratory exchange ratio — a marker of fuel preference shifting toward fats.
Body Composition & Metabolic Health
Preclinical models of diet-induced obesity have seen body weight reduction (~12–24%), reduction in white adipose tissue, improved glucose tolerance, and better insulin sensitivity, without changes in food intake.
Exercise-Mimetic Effects
SLU-PP-332 induces genetic and metabolic signatures similar to endurance training, including increased endurance capacity, higher mitochondrial content in muscle, enhanced capillary density, and shifts toward oxidative muscle fibers.
Cardiometabolic and Anti-Inflammatory Properties
Research suggests potential cardioprotective effects, reduced hepatic steatosis, and lowered markers of chronic inflammation (e.g., IL-6, TNF-α), indicating broader utility in metabolic and aging studies.
Clinical Studies
As of early 2026, SLU-PP-332 has not completed human clinical trials and remains preclinical, with evidence derived mostly from animal experiments and in vitro research.
Researchers at academic centers have proposed investigations into its exercise-like metabolic effects, but no regulatory-approved human data are available. It remains a tool for laboratory research into energy metabolism and mitochondrial biology rather than an approved therapy.
Safety, Side Effects, and Considerations
Safety Profile
- Not FDA-approved for human use: All human safety, dosing, and pharmacokinetics are unknown.
- Preclinical tolerability: Animal models report no acute organ toxicity at research doses, but long-term effects aren’t established.
- Mechanistic benefits: May influence metabolic and inflammatory signaling, but relevance to humans requires confirmation.
Side Effects & Risks
- Human side effects unknown: Without controlled clinical studies, real risk profiles can’t be defined.
- Research-only status: Often supplied with disclaimers against human consumption and intended strictly for laboratory work.
- Bioavailability questions: Some community reports question oral absorption and practical formulation, but scientific consensus is lacking.
Important Considerations
- SLU-PP-332 should only be handled within qualified research environments.
- Clinical efficacy and safety still need rigorous human studies before any therapeutic claims.
Summary
SLU-PP-332 is a preclinical research compound studied for its ability to activate mitochondrial and metabolic pathways linked to endurance and energy efficiency. By stimulating estrogen-related receptors, it promotes fat oxidation, mitochondrial biogenesis, and exercise-like metabolic signaling in preclinical models. While early findings are promising, SLU-PP-332 remains investigational, with no confirmed human safety or dosing data.
